1088 related articles for article (PubMed ID: 16115227)
1. Cytokeratin 7 and 20 expression in intestinal metaplasia of the distal oesophagus: relationship to gastro-oesophageal reflux disease.
Shearer C; Going J; Neilson L; Mackay C; Stuart RC
Histopathology; 2005 Sep; 47(3):268-75. PubMed ID: 16115227
[TBL] [Abstract][Full Text] [Related]
2. Cytokeratin immunoreactivity patterns in short-segment Barrett's esophagus in Japanese patients.
Yagi K; Nakamura A; Sekine A
J Gastroenterol Hepatol; 2005 Jun; 20(6):929-34. PubMed ID: 15946143
[TBL] [Abstract][Full Text] [Related]
3. Cytokeratin and DAS-1 immunostaining reveal similarities among cardiac mucosa, CIM, and Barrett's esophagus.
DeMeester SR; Wickramasinghe KS; Lord RV; Friedman A; Balaji NS; Chandrasoma PT; Hagen JA; Peters JH; DeMeester TR
Am J Gastroenterol; 2002 Oct; 97(10):2514-23. PubMed ID: 12385432
[TBL] [Abstract][Full Text] [Related]
4. Cytokeratin immunoreactivity of intestinal metaplasia at normal oesophagogastric junction indicates its aetiology.
Couvelard A; Cauvin JM; Goldfain D; Rotenberg A; Robaszkiewicz M; Fléjou JF;
Gut; 2001 Dec; 49(6):761-6. PubMed ID: 11709508
[TBL] [Abstract][Full Text] [Related]
5. Etiology of intestinal metaplasia at the gastroesophageal junction.
Balaji NS; DeMeester SR; Wickramasinghe KS; Hagen JA; Peters JH; DeMeester TR
Surg Endosc; 2003 Jan; 17(1):43-8. PubMed ID: 12364989
[TBL] [Abstract][Full Text] [Related]
6. Utilization of cytokeratins 7 and 20 does not differentiate between Barrett's esophagus and gastric cardiac intestinal metaplasia.
Mohammed IA; Streutker CJ; Riddell RH
Mod Pathol; 2002 Jun; 15(6):611-6. PubMed ID: 12065774
[TBL] [Abstract][Full Text] [Related]
7. Changing pattern of cytokeratin 7 and 20 expression from normal epithelium to intestinal metaplasia of the gastric mucosa and gastroesophageal junction.
Jovanovic I; Tzardi M; Mouzas IA; Micev M; Pesko P; Milosavljevic T; Zois M; Sganzos M; Delides G; Kanavaros P
Histol Histopathol; 2002 Apr; 17(2):445-54. PubMed ID: 11962749
[TBL] [Abstract][Full Text] [Related]
8. The association of short segment Barrett's esophagus with intestinal metaplasia in stomach.
Tuncer I; Ugraş S; Uygan I; Türkdoğan K; Kösem M
Turk J Gastroenterol; 2003 Mar; 14(1):33-8. PubMed ID: 14593535
[TBL] [Abstract][Full Text] [Related]
9. [Cytokeratin immunoreactivity patterns in the diagnosis of Barrett's esophagus].
Wang R; Xie J; Shen Y; Ren T
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Dec; 32(12):1820-3. PubMed ID: 23268419
[TBL] [Abstract][Full Text] [Related]
10. Cytokeratin immunoreactivity patterns in the diagnosis of short-segment Barrett's esophagus.
Ormsby AH; Vaezi MF; Richter JE; Goldblum JR; Rice TW; Falk GW; Gramlich TL
Gastroenterology; 2000 Sep; 119(3):683-90. PubMed ID: 10982762
[TBL] [Abstract][Full Text] [Related]
11. CagA-positive strains of Helicobacter pylori may protect against Barrett's esophagus.
Vaezi MF; Falk GW; Peek RM; Vicari JJ; Goldblum JR; Perez-Perez GI; Rice TW; Blaser MJ; Richter JE
Am J Gastroenterol; 2000 Sep; 95(9):2206-11. PubMed ID: 11007219
[TBL] [Abstract][Full Text] [Related]
12. Pathophysiological characteristics of the various forms of gastro-oesophageal reflux disease. Spectrum disease or distinct phenotypic presentations?
Frazzoni M; Manno M; De Micheli E; Savarino V
Dig Liver Dis; 2006 Sep; 38(9):643-8. PubMed ID: 16627016
[TBL] [Abstract][Full Text] [Related]
13. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
[TBL] [Abstract][Full Text] [Related]
14. Helicobacter pylori infection, not gastroesophageal reflux, is the major cause of inflammation and intestinal metaplasia of gastric cardiac mucosa.
Goldblum JR; Richter JE; Vaezi M; Falk GW; Rice TW; Peek RM
Am J Gastroenterol; 2002 Feb; 97(2):302-11. PubMed ID: 11866266
[TBL] [Abstract][Full Text] [Related]
15. Modified classification for adenocarcinoma of the gastro-oesophageal junction.
Shearer CJ; Going JJ; Neilson LJ; Stuart RC
ANZ J Surg; 2007 Jul; 77(7):544-9. PubMed ID: 17610690
[TBL] [Abstract][Full Text] [Related]
16. Review article: prevalence of Barrett's oesophagus and metaplasia at the gastro-oesophageal junction.
Sharma P
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():48-54; discussion 61-2. PubMed ID: 15456464
[TBL] [Abstract][Full Text] [Related]
17. Does Cytokeratin7/20 immunoreactivity help to distinguish Barrett's esophagus from gastric intestinal metaplasia? Results of a prospective study of 75 patients.
Schilling D; Spiethoff A; Rosenbaum A; Hartmann D; Eickhoff A; Jakobs R; Weickert U; Rebe M; Bohrer MH; Riemann JF
Pathol Res Pract; 2005; 200(11-12):801-5. PubMed ID: 15792123
[TBL] [Abstract][Full Text] [Related]
18. The extent of oesophageal acid exposure overlap among the different gastro-oesophageal reflux disease groups.
Shapiro M; Green C; Faybush EM; Esquivel RF; Fass R
Aliment Pharmacol Ther; 2006 Jan; 23(2):321-9. PubMed ID: 16393313
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of cytokeratin immunoreactivity pattern for distinction of Barrett's esophagus from intestinal metaplasia of the stomach.
Iwata T; Kurita N; Nishioka M; Hidenori M; Wakatsuki S; Sano T; Shimada M
Hepatogastroenterology; 2007 Sep; 54(78):1710-2. PubMed ID: 18019700
[TBL] [Abstract][Full Text] [Related]
20. Distinction between short-segment Barrett's esophageal and cardiac intestinal metaplasia.
Liu GS; Gong J; Cheng P; Zhang J; Chang Y; Qiang L
World J Gastroenterol; 2005 Oct; 11(40):6360-5. PubMed ID: 16419166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
